Specific targeting of oncogenic proteins includes K-Ras inhibitors, sotorasib (Lumakras) for advanced NSCLC with the K-Ras G12C mutation.260 Adagrasib (Krazati) resembles sotorasib. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.